Generex Biotechnology Corp, an integrated healthcare holding company, has filed a trademark for its li-Key vaccine, to be known as “The Complete Vaccine”. The partner of Bintai Kinden Corp Bhd has also filed a patent for its li-Key SARS-CoV-2 vaccine.
Bintai Kinden, a Malaysian investment holding company said the technology offers the safest and best route for the rapid development of a Covid-19 vaccine that can be safely administered to everyone, including children and pregnant women, without side effects.
Ong Choon Lui, Managing Director of Bintai Kinden stated that Generex has initiated good manufacturing practice production of several Covid-19 epitopes that will be formulated for the Phase I and Phase II clinical trials based on the results of the ex-vivo human studies.
“New drug application is being prepared for the United States’ Food and Drug Administration (FDA) submission in early 2021.
With multiple epitopes that are targeted to generate specific, neutralising regions of the coronavirus without off-target effects, and which have demonstrated positive T-cell regulation necessary for long-term immune memory, the Covid-19 vaccine has the potential to be a complete vaccine,” he explained.
Bintai Healthcare Sdn Bhd, a subsidiary of Bintai Kinden, was granted exclusive rights by Generex and its subsidiary, NuGenerex Immuno-Oncology Inc to distribute, sell and commercialise the Covid-19 vaccine in Malaysia and ASEAN countries.
It has also been given the first right of refusal to distribute and market the vaccine within Australia, New Zealand, and the global halal market.
